Mesoblast

Turing Pharmaceuticals launched

Wednesday, February 25, 2015

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

[Read More]

Osiris, Mesoblast enter agreement

Friday, October 11, 2013

Osiris Therapeutics, a stem cell company, has entered into an agreement with a wholly-owned subsidiary of Mesoblast for the sale of Osiris’ culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal, in a transaction worth up to $100 million. Additionally, Osiris will receive royalty payments on sales of Prochymal and other products utilizing the acquired ceMSC technology.

[Read More]